
Traditionally, enhancing the function of T cell-recruiting antibodies requires a labor-intensive two-step process: initial phage display screening for binding affinity and secondary screening for cytotoxic activity. In this study, we utilized the bispecific bivalent antibody framework 'BiBian' and combined VHH phage display with a domain library approach for the generation of antibodies that recruit T-cells, thereby facilitating this evolution. By leveraging the modular nature of the single-domain component, we bypassed the affinity pre-selection phase by directly grafting mutant VHH libraries onto the BiBian framework for immediate cytotoxicity screening. While conventional methods were limited to evaluating only six candidates for cytotoxicity out of 264 initial clones, this method enabled the direct functional assessment of all 264 clones. This comprehensive approach significantly reduced the risk of overlooking high-potency variants that may not exhibit a linear correlation between binding affinity and functional output. Ultimately, three antibodies identified via this method exhibited a lower IC50 for cytotoxic activity (down to 0.05 nM) than the top-performing candidate obtained through traditional methods (0.30 nM). In this proof-of-concept study, this accelerated functional-first strategy enabled the rapid evaluation of candidate potency within the target bivalent format. While further validation across other targets and antibody formats will be required to confirm broader applicability, these findings highlight the potential of the Dolag-ArT strategy for direct functional screening.
Specialized pro-resolving mediators (SPMs) actively promote the resolution of inflammation, but their scalable and food-compatible production remains challenging because current methods rely on multistep chemical synthesis, mammalian cells, purified enzymes, crude enzyme preparations, or recombinant microorganisms. Here, we developed a scalable, food-compatible submerged-cultured whole-cell biocatalytic process for the production of resolvin D5 (RvD5; 7S,17S-dihydroxydocosahexaenoic acid) from docosahexaenoic acid (DHA) using the edible mushroom Pleurotus ostreatus. Submerged-cultured P. ostreatus whole cells stereoselectively converted DHA to RvD5 via a 17S-hydroxydocosahexaenoic acid intermediate through an endogenous lipoxygenase (LOX)-mediated double-oxygenation pathway, without enzyme purification or heterologous gene expression. Optimization of submerged cultivation conditions (cultivation period and medium composition) increased RvD5 production by 2.1-fold, and subsequent optimization of whole-cell biotransformation parameters (temperature, pH, cell and substrate concentrations, polyvinylpyrrolidone and ethanol supplementation, reaction time, and agitation) resulted in an overall 13.4-fold increase relative to the initial conditions. Under the optimized flask-scale conditions, whole cells produced 2.14 mM (0.77 g/L) RvD5 from 2.5 mM DHA with an 85.6% molar yield within 40 min. The process was successfully scaled up to a 3.0-L stirred-tank bioreactor (1.0-L working volume), producing 2.08 mM (0.75 g/L) RvD5 with an 83.2% molar yield within 60 min. The developed cultivation-based edible fungal whole-cell biocatalytic process integrates catalyst preparation, efficient RvD5 biosynthesis, and scalable bioprocessing, providing a practical strategy for the scalable biotechnological production of DHA-derived SPMs.
The 4-hydroxyvalerate (4HV) is a key intermediate that serves as a precursor for γ-valerolactone (GVL) and terpolymers, contributing to the synthesis of liquid fuels and biodegradable plastics with improved properties. While 4HV is typically derived from levulinic acid (LA) via chemical catalysis, these methods are limited by high costs and operational complexity. In our previous study, we designed an engineered Pseudomonas putida KT2440 with double knockout of pcaIJ and lvaR and introduction of aroG, asbF, and adc, enabling high production of LA from glycerol. Herein, we introduced acyl-CoA synthetase gene (lvaE) and 4-hydroxyvaleryl-CoA dehydratase gene (lvaD) into LA producing strain to construct a 4HV production pathway from glycerol. The strain harboring both lvaD and lvaE consumed the highest amount of LA, and, subsequently, showed the highest 4HV production. In fed batch fermentation, P. putida KT2440 HP403 produced 28.77 mM of 4HV from glycerol. To expand its potential applications as a PHA precursor, biologically synthesized 4HV was supplied to the high-performing PHA producer Cupriavidus necator PHB−4/phaCBP-M-CPF4 for polymer synthesis. This produced a terpolymer with the composition P(54.49 mol% 3HB-co-6.98 mol% 3HV-co-38.53 mol% 4HV) with a PHA content of 60.21%. The terpolymer exhibited improved elongation at break and lower glass transition and crystallization temperatures due to increased amorphicity. This study suggests a 4HV bioconversion strategy derived from glycerol by engineered P. putida KT2440 HP403 and demonstrates the production of a high-content P(3HB-co-3HV-co-4HV) terpolymer in C. necator containing high-mole fraction of 4HV, thereby providing a new sustainable approach for PHA production.
Chitooligosaccharides (COS) are versatile biomolecules with applications across food, pharmaceutical, and cosmetic industries. Expanding the COS portfolio, particularly with partially acetylated COS (paCOS) possessing defined structural characteristics, including degree of deacetylation and pattern of acetylation, is essential for advancing structure-function studies and enabling tailored applications. This study investigates the heterologous co-expression of chitin deacetylases (CDAs) with a chitin oligosaccharide synthase (oCS) RhNodC in Escherichia coli for the in vivo production of paCOS. Although this approach enables paCOS formation, co-expression of NodC and CDAs results in reduced COS yields and incomplete conversion of fully acetylated COS into paCOS. To identify potential cellular bottlenecks underlying these limitations, stress responses were monitored using a stress promoter-based fluorescent reporter system. CDA co-expression activated protein quality control and membrane-associated stress responses. Furthermore, confocal microscopy revealed altered intracellular localization of both RhNodC and CDAs compared to individual expression, with enzymes detected in the cytoplasm, membrane and inclusion bodies. Co-expression also resulted in pronounced cellular elongation, further indicating cellular stress during pathway implementation. Together, these findings reveal cellular bottlenecks associated with enzyme co-expression and highlight the need for deeper exploration of RhNodC-CDA co-expression and approaches to mitigate cellular stress to improve in vivo paCOS production.